Granexin as a topical therapeutic to mitigate cutaneous radiation injury
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93021C00009
- Awardee
-
Xequel Bio, Inc. UEI T4JKC8B27PJ7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $6,618,886
Award facts
- Opportunity
-
- 2020 NIAID Omnibus Broad Agency Announcement Pre-Solicitation · HHSNIHNIAIDBAA20201 · Posted Dec 11, 2019
- 2020 NIAID Omnibus Broad Agency Announcement Award Notice · Posted Mar 16, 2021
- 2020 NIAID Omnibus Broad Agency Announcement Solicitation · Posted Jan 3, 2020
- Contract value 100% obligated
- $6,618,886.46 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 5 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Mt Pleasant, SC 29464, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$1,842 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $137,994 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $500,000 | |
| Exercise an Option | $1,631,855 | |
| Vendor DUNS or Name Change - Non-Novation | $1,007,117 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $1,650,013 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,693,749 |
Show all 12
About this award
The National Institute of Allergy and Infectious Diseases awarded a $6.6 million definitive contract to Xequel Bio, Inc. for development of Granexin as a topical therapeutic to mitigate cutaneous radiation injury on March 16, 2021.
The originating pre-solicitation notice, posted December 11, 2019, sought proposals for advanced vaccine and therapeutic candidates, medical countermeasures, and diagnostics targeting infectious diseases and public health threats. Potential awards across the solicitation ranged from $2 million to $11.5 million total cost. Place of performance is Mt. Pleasant, SC.
The contract carries a cost-plus-fixed-fee pricing structure with an ultimate completion date of February 28, 2025. The award note indicates administrative de-obligation of unexpended fiscal year 2021 funding in accordance with 31 U.S.C. Section 1552(a) in preparation for September 30, 2026 closing.
Across reported fiscal years, the contract invoiced $6.3 million in government payments spanning FY2021 through FY2024. Most recent labor footprint (FY2024) reflects 0.6 FTEs across 1,226 contractor hours, with derived government-paid hourly rates rising from $835.45/hour in FY2021 to $1,679.67/hour in FY2024. Xequel Bio self-performed all reported hours with no subcontractors.
Quick answers
Who was awarded contract 75N93021C00009?
75N93021C00009 was awarded to Xequel Bio, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on March 16, 2021.
How much is contract 75N93021C00009 worth?
The government has obligated $6,618,886 on 75N93021C00009.
Was contract 75N93021C00009 competed?
The extent of competition for 75N93021C00009 was full and open competition. The government received 5 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award